Budd-Chiari Syndrome Clinical Presentation
- Author: Praveen K Roy, MD, AGAF; Chief Editor: BS Anand, MD more...
The classic triad of abdominal pain, ascites, and hepatomegaly is observed in the vast majority of patients with Budd-Chiari syndrome, but it is nonspecific. A high index of suspicion is needed to make the diagnosis.
If the liver has had time to develop collaterals and decompress, patients can be asymptomatic (≤20% ) or present with few symptoms. As the syndrome progresses, however, it can lead to liver failure and portal hypertension with corresponding symptoms (eg, encephalopathy, hematemesis). The American Association for the Study of Liver Diseases has released guidelines for the management of acute liver failure.
The clinical variants of Budd-Chiari syndrome have been described as follows[5, 6, 7] :
Acute and subacute forms: Characterized by rapid development of abdominal pain, ascites, hepatomegaly, jaundice, and renal failure.
Chronic form: Most common presentation; patients present with progressive ascites; jaundice is absent; approximately 50% of patients also have renal impairment
Fulminant form: Uncommon presentation; fulminant or subfulminant hepatic failure is present, along with ascites, tender hepatomegaly, jaundice, and renal failure.
Patients with acute onset of obstruction typically present with acute right upper quadrant pain. Abdominal distention can also be a significant symptom, because of ascites. Jaundice is rarely observed.
Physical examination may reveal the following findings:
Prominence of collateral veins
Khuroo MS, Al-Suhabani H, Al-Sebayel M, et al. Budd-Chiari syndrome: long-term effect on outcome with transjugular intrahepatic portosystemic shunt. J Gastroenterol Hepatol. 2005 Oct. 20(10):1494-502. [Medline].
Montano-Loza AJ, Tandon P, Kneteman N, Bailey R, Bain VG. Rotterdam score predicts early mortality in Budd-Chiari syndrome, and surgical shunting prolongs transplant-free survival. Aliment Pharmacol Ther. 2009 Nov 15. 30(10):1060-9. [Medline].
Valla DC. Primary Budd-Chiari syndrome. J Hepatol. 2009 Jan. 50(1):195-203. [Medline].
Segev DL, Nguyen GC, Locke JE, et al. Twenty years of liver transplantation for Budd-Chiari syndrome: a national registry analysis. Liver Transpl. 2007 Sep. 13(9):1285-94. [Medline].
Aydinli M, Bayraktar Y. Budd-Chiari syndrome: etiology, pathogenesis and diagnosis. World J Gastroenterol. 2007 May 21. 13(19):2693-6. [Medline].
Darwish Murad S, Plessier A, Hernandez-Guerra M,et al. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med. 2009 Aug 4. 151(3):167-75. [Medline].
Chaudhuri M, Jayaranganath M, Chandra VS. Percutaneous recanalization of an occluded hepatic vein in a difficult subset of pediatric Budd-Chiari syndrome. Pediatr Cardiol. 2012 Jun. 33(5):806-10. [Medline].
Paradis V, Bieche I, Dargere D, et al. Quantitative gene expression in Budd-Chiari syndrome: a molecular approach to the pathogenesis of the disease. Gut. 2005 Dec. 54(12):1776-81. [Medline]. [Full Text].
Tian ZL, Jia GL, Xi HL, Feng S, Wang XK, Li R. Investigation on etiology of hepatic venous obstruction Budd-Chiari syndrome. Cell Biochem Biophys. 2014 Dec. 70(3):1803-6. [Medline].
Rautou PE, Angermayr B, Garcia-Pagan JC, et al. Pregnancy in women with known and treated Budd-Chiari syndrome: maternal and fetal outcomes. J Hepatol. 2009 Jul. 51(1):47-54. [Medline].
Moucari R, Rautou PE, Cazals-Hatem D, et al. Hepatocellular carcinoma in Budd-Chiari syndrome: characteristics and risk factors. Gut. 2008 Jun. 57(6):828-35. [Medline].
Rajani R, Melin T, Bjornsson E, et al. Budd-Chiari syndrome in Sweden: epidemiology, clinical characteristics and survival - an 18-year experience. Liver Int. 2009 Feb. 29(2):253-9. [Medline].
Ki M, Choi HY, Kim KA, Kim BH, Jang ES, Jeong SH. Incidence, prevalence, and complications of Budd-Chiari syndrome in South Korea: a nationwide, population-based study. Liver Int. 2015 Nov 12. [Medline].
Qi X, Ren W, Wang Y, Guo X, Fan D. Survival and prognostic indicators of Budd-Chiari syndrome: a systematic review of 79 studies. Expert Rev Gastroenterol Hepatol. 2015 Jun. 9 (6):865-75. [Medline].
Liu FY, Wang MQ, Duan F, Fan QS, Song P, Wang Y. Hepatocellular carcinoma associated with Budd-Chiari syndrome: imaging features and transcatheter arterial chemoembolization. BMC Gastroenterol. 2013 Jun 24. 13:105. [Medline]. [Full Text].
Goel RM, Johnston EL, Patel KV, Wong T. Budd-Chiari syndrome: investigation, treatment and outcomes. Postgrad Med J. 2015 Dec. 91 (1082):692-7. [Medline].
[Guideline] Lee WM, Larson AM, Stravitz T. AASLD position paper: the management of acute liver failure: update 2011. National Guideline Clearinghouse. September 2011. Available at http://guideline.gov/content.aspx?id=36894&search=liver+failure. Accessed: Nov 3, 2014.
Hwang HJ, Kim KW, Jeong WK, et al. Hepatic outflow obstruction at middle hepatic vein tributaries or inferior right hepatic veins after living donor liver transplantation with modified right lobe graft: comparison of CT and Doppler ultrasound. AJR Am J Roentgenol. 2009 Sep. 193(3):745-51. [Medline].
Song HP, Yu M, Zhang M, et al. Diagnosis of active hemorrhage from the liver with contrast-enhanced ultrasonography after percutaneous transhepatic angioplasty and stent placement for Budd-Chiari syndrome. J Ultrasound Med. 2009 Jul. 28(7):955-8. [Medline].
Virmani V, Khandelwal N, Kang M, Gulati M, Chawla Y. MDCT venography in the evaluation of inferior vena cava in Budd-Chiari syndrome. Indian J Gastroenterol. 2009 Jan-Feb. 28(1):17-23. [Medline].
Cheng D, Xu H, Hua R, et al. Comparative study of MRI manifestations of acute and chronic Budd-Chiari syndrome. Abdom Imaging. 2015 Jan. 40(1):76-84. [Medline].
Garcia-Pagan JC, Heydtmann M, Raffa S, et al. TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology. 2008 Sep. 135(3):808-15. [Medline].
Hasija RP, Nagral A, Marar S, Bavdekar AR. Transjugular intrahepatic portosystemic shunt (TIPSS) for Budd Chiari syndrome. Indian Pediatr. 2010 Jun. 47(6):527-8. [Medline].
Fitsiori K, Tsitskari M, Kelekis A, Filippiadis D, Triantafyllou K, Brountzos E. Transjugular intrahepatic portosystemic shunt for the treatment of Budd-Chiari syndrome patients: results from a single center. Cardiovasc Intervent Radiol. 2014 Jun. 37(3):691-7. [Medline].
Van Brusselen D, Janssen CE, Scott C, et al. Budd-Chiari syndrome as presenting symptom of hepatic sarcoidosis in a child, with recurrence after liver transplantation. Pediatr Transplant. 2012 Mar. 16(2):E58-62. [Medline].
Tang TJ, Batts KP, de Groen PC, et al. The prognostic value of histology in the assessment of patients with Budd-Chiari syndrome. J Hepatol. 2001 Sep. 35(3):338-43. [Medline].
Sun YL, Fu Y, Zhou L, Ma XX, Wang ZW, Wu Y. Staged management of Budd-Chiari syndrome caused by co-obstruction of the inferior vena cava and main hepatic veins. Hepatobiliary Pancreat Dis Int. 2013 Jun. 12(3):278-85. [Medline].
Horton JD, San Miguel FL, Ortiz JA. Budd-Chiari syndrome: illustrated review of current management. Liver Int. 2008 Apr. 28(4):455-66. [Medline].
Copelan A, Remer EM, Sands M, Nghiem H, Kapoor B. Diagnosis and management of Budd Chiari syndrome: an update. Cardiovasc Intervent Radiol. 2015 Feb. 38 (1):1-12. [Medline].
Mancuso A. An update on the management of Budd-Chiari syndrome: the issues of timing and choice of treatment. Eur J Gastroenterol Hepatol. 2015 Mar. 27 (3):200-3. [Medline].
Hermeziu B, Franchi-Abella S, Plessier A, et al. Budd-Chiari syndrome and essential thrombocythemia in a child: favorable outcome after transjugular intrahepatic portosystemic shunt. J Pediatr Gastroenterol Nutr. 2008 Mar. 46(3):334-7. [Medline].
Murad SD, Luong TK, Pattynama PM, et al. Long-term outcome of a covered vs. uncovered transjugular intrahepatic portosystemic shunt in Budd-Chiari syndrome. Liver Int. 2008 Feb. 28(2):249-56. [Medline].
Panagiotou I, Kelekis DA, Karatza C, et al. Treatment of Budd-Chiari syndrome by transjugular intrahepatic portosystemic shunt. Hepatogastroenterology. 2007 Sep. 54(78):1813-6. [Medline].
Wu X, Ding W, Cao J, Han J, Li J. Modified transjugular intrahepatic portosystemic shunt in the treatment of Budd-Chiari syndrome. Int J Clin Pract. 2010 Mar. 64(4):460-4. [Medline].
Ulrich F, Pratschke J, Neumann U, et al. Eighteen years of liver transplantation experience in patients with advanced Budd-Chiari syndrome. Liver Transpl. 2008 Feb. 14(2):144-50. [Medline].
Oldakowska-Jedynak U, Ziarkiewicz M, Ziarkiewicz-Wroblewska B, et al. Myeloproliferative neoplasms and recurrent thrombotic events in patients undergoing liver transplantation for Budd-Chiari syndrome: a single-center experience. Ann Transplant. 2014 Nov 14. 19:591-7. [Medline].
Cura M, Haskal Z, Lopera J. Diagnostic and interventional radiology for Budd-Chiari syndrome. Radiographics. 2009 May-Jun. 29(3):669-81. [Medline].
Ren W, Qi X, Yang Z, Han G, Fan D. Prevalence and risk factors of hepatocellular carcinoma in Budd-Chiari syndrome: a systematic review. Eur J Gastroenterol Hepatol. 2013 Jul. 25(7):830-41. [Medline].
Li T, Zhai S, Pang Z, et al. Feasibility and midterm outcomes of percutaneous transhepatic balloon angioplasty for symptomatic Budd-Chiari syndrome secondary to hepatic venous obstruction. J Vasc Surg. 2009 Nov. 50(5):1079-84. [Medline].